SCHEMBL734130

SCHEMBL734130

COC(=O)C(CC=O)N1CCN(c2cccc(OC(F)(F)F)c2)C(C)C1=O

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.38
MCHR1 Q99705 1/20 0.37
FFAR4 Q5NUL3 1/20 0.36
ACACB O00763 1/20 0.36
CHRM2 P08172 2/20 0.36
CHRM1 P11229 1/20 0.36
CHRM4 P08173 3/20 0.36
HCRTR1 O43613 3/20 0.35
HCRTR2 O43614 3/20 0.35
DRD2 P14416 2/20 0.35
DRD3 P35462 2/20 0.35
KCNH2 Q12809 2/20 0.35
PIM1 P11309 2/20 0.35
TAS1R3 Q7RTX0 1/20 0.35
TAS1R1 Q7RTX1 1/20 0.35
TAS1R2 Q8TE23 1/20 0.35
SLC5A1 P13866 2/20 0.34
NLRP3 Q96P20 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27832141 0.92 NOTUM (0.42) NOTUMMCHR1FFAR4ACACBCHRM2
SCHEMBL733975 0.88 NOTUM (0.41) NOTUMMCHR1FFAR4ACACBCHRM2
SCHEMBL734643 0.88 HSD17B10 (0.44)
SCHEMBL735359 0.81 NOTUM (0.41) NOTUMFFAR4ACACBCHRM2CHRM1
SCHEMBL735360 0.81 NOTUM (0.41) NOTUMFFAR4ACACBCHRM2CHRM1
SCHEMBL27933836 0.81 NOTUM (0.45) NOTUMMCHR1FFAR4ACACBCHRM2
SCHEMBL734524 0.80 NOTUM (0.36) NOTUMMCHR1ACACBCHRM2CHRM1
SCHEMBL734490 0.80 LIPE (0.36) NOTUMMCHR1FFAR4ACACBCHRM2
SCHEMBL734489 0.80 LIPE (0.36) NOTUMMCHR1FFAR4ACACBCHRM2
SCHEMBL27832131 0.80 NOTUM (0.39) NOTUMMCHR1FFAR4ACACBCHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8138175-B2 Heterocyclyl compounds HOFFMANN-LA ROCHE INC. (US) 2012-03-20 US disclosed
CN-102112451-A Diazepan and piperazine derivatives modulators of chemokine receptors HOFFMANN LA ROCHE 2011-06-29 CN disclosed
EP-2321285-A1 DIAZEPAN AND PIPERAZINE DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS F. Hoffmann-La Roche AG (CH) 2011-05-18 EP disclosed
WO-2010012619-A1 DIAZEPAN AND PIPERAZINE DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS F. HOFFMANN-LA ROCHE AG (CH) 2010-02-04 WO disclosed
US-20100022518-A1 NOVEL HETEROCYCLYL COMPOUNDS HOFFMANN-LA ROCHE, INC. 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022518-A1 NOVEL HETEROCYCLYL COMPOUNDS CCR2, CCR3, CCR5 NOTUM 4344/4885MCHR1 192/4885FFAR4 471/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.